Weed (BUDZ) Share-based Compensation (2010 - 2025)

Weed (BUDZ) posted quarterly Share-based Compensation of $75000.0 for Q4 2025, up 400.0% quarter-over-quarter from $15000.0 in Q1 2025.

Weed (BUDZ) Share-based Compensation (2010 - 2025) Analysis & Trends

Weed's Share-based Compensation history runs 11 years deep, the most recent figure standing at $75000.0 for Q4 2025.

In Q4 2025, Share-based Compensation changed N/A year-over-year to $75000.0; the TTM figure through Mar 2026 stood at $75000.0 (up 158.62% YoY), while the FY2025 annual figure was $90000.0, up 542.86% from the prior year.
Share-based Compensation for Q4 2025 stood at $75000.0, up from $15000.0 in the prior quarter.
The five-year high for Share-based Compensation was $1.0 million in Q2 2021, with the low at -$45000.0 in Q3 2023.
The 5-year median for Share-based Compensation is $75000.0 (2025), against an average of $187363.3.
Peak annual rise in Share-based Compensation reached 300.0% in 2023, while the deepest fall reached 154.02% in 2023.
Weed's Share-based Compensation stood at $216000.0 in 2021, then plunged by 89.58% to $22500.0 in 2022, then jumped by 300.0% to $90000.0 in 2023, then sank by 84.44% to $14000.0 in 2024, then surged by 435.71% to $75000.0 in 2025.
Business Quant data shows BUDZ's Share-based Compensation at $75000.0 in Q4 2025, $15000.0 in Q1 2025, and $14000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Stock Comp. (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-	-
2	Teva Pharmaceutical Industries	42.95 Bn	39.30 Bn	2.15 Bn	40.00 Mn
3	Zoetis	31.58 Bn	29.90 Bn	1.05 Bn	26.00 Mn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	114.12 Mn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	19.00 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	30.40 Mn
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn	65.00 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	7.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-	-
10	Weed	2.88 Mn	2.88 Mn	-	-

Download Data